ePoster
100% Page: /
Abstracts/Presentation Description
Lu Shezmeen Binti Mohd Harris Lu1, Siamak Sakhaie2
1Department of Anatomical Pathology, Frankston Hospital Dorevitch Pathology, VIC, Australia.
Abstract:
Ovarian large cell neuroendocrine carcinoma (LCNEC) is an extremely rare and aggressive malignancy, accounting for less than 2% of ovarian malignancies and neuroendocrine tumours of the female genital tract. It is frequently associated with other ovarian epithelial neoplasms.[1,2] Clinical diagnosis is challenging due to non-specific symptoms, therefore, histological and immunohistochemical confirmation is paramount in establishing an accurate diagnosis. Recognising this entity is crucial, due to its treatment implications and poor prognosis, with a median overall survival of 10 months, and 1 year overall survival rate of 47.1 %. [3] We report a case of a 70 year old female presenting to the hospital with abdominal distension and pain. A CT scan revealed a 10 cm left pelvic mass with retroperitoneal lymphadenopathy. A bilateral salpingo-oophorectomy was performed, and histological assessment confirmed a LCNEC arising from a borderline mucinous tumour with microinvasive carcinoma. The LCNEC was composed of solid sheets and nests of large cells with moderate amphophilic granular cytoplasm, large irregular nuclei with stippled chromatin, and prominent nucleoli. Mitoses were frequent, with abundant apoptotic debris and necrosis. Immunohistochemistry showed paranuclear dot-like staining with AE1/AE3, positivity with neuroendocrine markers synaptophysin and CD56, and a Ki-67 proliferation index well over 90%.
References:
1. Xing, Y. et al. Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with low-level her-2 expression: A case report. Frontiers 2024;14. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1339806/full. Accessed 31 October 2024.
2. Gupta P, Bagga R, Rai B, Srinivasan R. primary pure large cell neuroendocrine carcinoma of the ovary: histopathologic and immunohistochemical analysis with review of the literature. Int J Clin Exp Pathol. 2021; 14(9):1000-1009. https://pmc.ncbi.nlm.nih.gov/articles/PMC8493259/. Accessed 31 October 2024.
1Department of Anatomical Pathology, Frankston Hospital Dorevitch Pathology, VIC, Australia.
Abstract:
Ovarian large cell neuroendocrine carcinoma (LCNEC) is an extremely rare and aggressive malignancy, accounting for less than 2% of ovarian malignancies and neuroendocrine tumours of the female genital tract. It is frequently associated with other ovarian epithelial neoplasms.[1,2] Clinical diagnosis is challenging due to non-specific symptoms, therefore, histological and immunohistochemical confirmation is paramount in establishing an accurate diagnosis. Recognising this entity is crucial, due to its treatment implications and poor prognosis, with a median overall survival of 10 months, and 1 year overall survival rate of 47.1 %. [3] We report a case of a 70 year old female presenting to the hospital with abdominal distension and pain. A CT scan revealed a 10 cm left pelvic mass with retroperitoneal lymphadenopathy. A bilateral salpingo-oophorectomy was performed, and histological assessment confirmed a LCNEC arising from a borderline mucinous tumour with microinvasive carcinoma. The LCNEC was composed of solid sheets and nests of large cells with moderate amphophilic granular cytoplasm, large irregular nuclei with stippled chromatin, and prominent nucleoli. Mitoses were frequent, with abundant apoptotic debris and necrosis. Immunohistochemistry showed paranuclear dot-like staining with AE1/AE3, positivity with neuroendocrine markers synaptophysin and CD56, and a Ki-67 proliferation index well over 90%.
References:
1. Xing, Y. et al. Trastuzumab deruxtecan effectively controlled recurrent ovarian large-cell neuroendocrine carcinoma with low-level her-2 expression: A case report. Frontiers 2024;14. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1339806/full. Accessed 31 October 2024.
2. Gupta P, Bagga R, Rai B, Srinivasan R. primary pure large cell neuroendocrine carcinoma of the ovary: histopathologic and immunohistochemical analysis with review of the literature. Int J Clin Exp Pathol. 2021; 14(9):1000-1009. https://pmc.ncbi.nlm.nih.gov/articles/PMC8493259/. Accessed 31 October 2024.
3. Qui J, Xu J, Yao G, Zhu F, Wang Y, Fu Y. An ovarian large-cell neuroendocrine carcinoma accompanied by clear cell carcinoma with specific high level of AFP: Case Report and Review of the Literature. Cancer Manag Res. 2022 Jul 22;14:2235-2241. https://pmc.ncbi.nlm.nih.gov/articles/PMC9326035/. Accessed 21 November 2024.
DECLARATION OF PERSONAL CONTRIBUTION
I, Lu Shezmeen Binti Mohd Harris Lu, declare that the above abstract was my own original idea and written fully by myself.
Date: 27th of November, 2024.
Date: 27th of November, 2024.
Speaker/Presenting Authors
Authors
Submitting/Presenting Authors
Dr. Lu Shezmeen Binti Mohd Harris Lu - - Dorevitch Pathology, Frankston hospital (Victoria, Australia)